Macrophage NADPH oxidase activation, impaired cholesterol fluxes, and increased cholesterol biosynthesis in diabetic mice: A stimulatory role for d-glucose

Atherosclerosis

Volumn 195, Issue 2, 2007, Pages 277-286

  Hayek, Tony ^a   Kaplan, Marielle ^b   Kerry, Rachel ^a   Aviram, Michael ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Atherosclerosis; Cholesterol biosynthesis; Diabetes; Macrophages; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 2; CHOLESTEROL; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN; PEROXIDE; PRAVASTATIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SCAVENGER RECEPTOR; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVATION; LIPID METABOLISM; MACROPHAGE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; UPREGULATION;

ANIMALS; ANTIGENS, CD36; ARYLDIALKYLPHOSPHATASE; CELL LINE; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FOAM CELLS; GLUCOSE; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MICE; NADPH OXIDASE; OXIDATIVE STRESS;

EID: 36049008500     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.12.026     Document Type: Article

References (32)

1. Garcia M.J., McNamara P.M., Gordon T., and Kannel W.B. Morbidity and mortality in diabetics in the Framingham population: sixteen year follow-up study. Diabetes 23 (1974) 105-111
2. Uusitopa M.I., Niskanen L.K., Siitonen O., Voutilainen E., and Pyorala K. Five-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation 82 (1990) 27-36
3. Lusis A.J. Atherosclerosis. Nature 407 (2000) 233-241
4. Aviram M. Review of human studies on oxidative damage and antioxidant protection related to cardiovascular diseases. Free Radic Res 33 (2000) S85-S97
5. Steinberg D., and Lewis A. Oxidative modification of LDL and atherogenesis. Circulation 95 (1997) 1062-1071
6. Berliner J.A., Navab M., Fogelman A.M., et al. Atherosclerosis: Basic mechanisms: oxidation inflammation and genetics. Circulation 91 (1995) 2488-2496
7. Aviram M., Hardak E., Vaya J., et al. Human serum paraoxonases Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 30 (2000) 2510-2517
8. Rosenblat M., Draganov D., Watson C.E., et al. Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress. Arterioscler Thromb Vasc Biol 23 (2003) 468-474
9. Rosenblat M., and Aviram M. Nutritional pharmacological and metabolic influences on paraoxonase. Curr Opin Lipidol 16 (2005) 393-399
10. Aviram M., and Rosenblat M. Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipidol 16 (2005) 393-399
11. Maziere C., Auclair M., Rose-Robert F., Leflon P., and Maziere J.C. Glucose-enriched medium enhances cell-mediated low density lipoprotein peroxidation. FEBS Lett 363 (1995) 277-279
12. Griffin E., Re A., Hamel N., et al. A link between diabetes and atherosclerosis: glucose regulates expression of CD36 at the level of translation. Nat Med 7 (2001) 840-846
13. Hayek T., Hussein K., Aviram M., et al. Macrophage-foam cell formation in streptozotocin-induced diabetic mice: stimulatory effect of glucose. Atherosclerosis 183 (2005) 25-33
14. Aviram M., Rosenblat M., Bisgaier C.L., et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 101 (1998) 1581-1590
15. 2 in cultured endothelial cells. Arch Biochem Biophys 302 (1993) 348-355
16. 0 mice and from human carotid artery contain lipid peroxides and oxysterols. Biochem Biophys Res Commun 269 (2000) 775-780
17. Aviram M., and Vaya J. Markers for LDL oxidation. Methods Enzymol 335 (2001) 244-256
18. Shamir R., Hartman C., Karry R., et al. Paraoxonases (PONs) 1, 2, 3 are expressed in human and in mice gastrointestinal tract and in human intestinal Caco2cell line: selective secretion of PON1 and PON2. Free Radic Biol Res 39 (2005) 336-344
19. Johnston R.B., Keele Jr. B.B., Mirsa H.P., et al. The role of superoxide anion generation in phagocytic bactericidal activity. J Clin Invest 55 (1975) 1357-1372
20. Kaplan M., Aviram M., Knopf C., and Keidar S. Angiotensin II reduces macrophage cholesterol efflux: a role for the AT-1 receptor but not for the ABC1 transporter. Biochem Biophys Res Commun 290 (2002) 1529-1534
21. Fuhrman B., Volkova N., and Aviram M. Pomegranate juice inhibits oxidized LDL uptake and cholesterol biosynthesis in macrophages. J Nutr Biochem 16 (2005) 570-576
22. 2-like activity and lysophosphatidylcholine formation. Arterioscler Thromb Vasc Biol 23 (2003) 461-467
23. Han J., Hajjar D.P., Febbraio M., and Nicholson A.C. Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36. J Biol Chem 272 (1997) 21654-21659
24. Mietus-Snyder M., Gowri M.S., and Pitas R.E. Class A scavenger receptor up-regulation in smooth muscle cells by oxidized low density lipoprotein. Enhancement by calcium flux and concurrent cyclooxygenase-2 up-regulation. J Biol Chem 275 (2000) 17661-17670
25. Iida K.T., Kawakami Y., Suzuki H., et al. PPAR gamma ligands, troglitazone and pioglitazone, up-regulate expression of HMG-CoA synthase and HMG-CoA reductase gene in THP-1 macrophages. FEBS Lett 520 (2002) 177-181
26. Rosenblat M., and Aviram M. Oxysterol-induced activation of macrophage NADPH-oxidase enhances cell-mediated oxidation of LDL in the atherosclerotic apolipoprotein E deficient mouse: inhibitory role for vitamin E. Atherosclerosis 160 (2002) 69-80
27. Cathcart M.K. Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages: contributions to atherosclerosis. Arterioscler Thromb Vasc Biol 24 (2004) 23-28 2003
28. Mackness B., McElduff P., and Mackness M.I. J Intern Med 258 (2005) 363-368
29. Rosenblat M., Karry R., and Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes. Atherosclerosis 187 (2006) 74-81
30. Lagor W.R., de Groh E.D., and Nes G.C. Diabetes alters the occupancy of the hepatic 3-hydroxy-3-methylglutaryl-CoA reductase promoter. J Biol Chem 280 (2005) 36601-36608
31. Rosenson R.S. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. Am J Cardiovasc Drugs 1 (2001) 411-420
32. Fukuhara-Takaki K., Sakai M., Sakamoto Y., Takeya M., and Horiuchi S. Expression of class A scavenger receptor is enhanced by high glucose in vitro and under diabetic conditions in vivo: one mechanism for an increased rate of atherosclerosis in diabetes. J Biol Chem 280 (2005) 3355-3364